[vc_row content_width=”grid” css=”.vc_custom_1516178432909{padding-top: 80px !important;padding-bottom: 80px !important;}”][vc_column offset=”vc_col-lg-5 vc_col-md-12″][vc_single_image image=”8330″ img_size=”full”][\/vc_column][vc_column offset=”vc_col-lg-7 vc_col-md-12″ css=”.vc_custom_1516178424937{padding-right: 50px !important;padding-left: 50px !important;}”][vc_empty_space height=”25px”][vc_column_text]Harald Reinhart, M.D., has been our Venture Partner since 2025.\u00a0 He is the CEO of Allphase Pharma Consulting LLC. \u00a0He currently also serves as Adjunct Clinical Professor of infectious diseases at Yale School of Medicine. \u00a0Prior to his retirement in June 2024, he served as President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) at Zai Lab (NASDAQ: ZLAB; HKEX: 9688). \u00a0He leveraged his experience in infectious diseases to significantly expand the Company\u2019s capabilities in autoimmune and neuroscience. \u00a0Dr. Reinhart previously worked at Shionogi US as Head of Clinical Development and Medical Affairs, directing a broad portfolio of antibiotics, diabetes, allergy and pain medications.\u00a0 He guided several compounds through regulatory meetings, and obtained approval for ospemifene. Between 2003 and 2011, he held senior roles at Novartis where he oversaw successful filings of SNDAs and NDAs for Coartem, Famvir, Sebivo, and Cubicin, managed clinical development groups for infectious disease, immunity, transplantation, and renal disease.\u00a0 He supervised the transitioning of research projects into clinical developmenmt.\u00a0 In the years before, he was International Clinical Project Manager in charge of ciprofloxacin and acarbose at Bayer Corp., with several successful SNDAs and approvals.<\/p>\n
<\/p>\n
Dr. Reinhart holds a medical degree from the University of W\u00fcrzburg in Germany where he trained in anesthesiology. He completed his medical specialty training in the United States with board-certifications in internal medicine and infectious diseases.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"
[vc_row content_width=”grid” css=”.vc_custom_1516178432909{padding-top: 80px !important;padding-bottom: 80px !important;}”][vc_column offset=”vc_col-lg-5 vc_col-md-12″][vc_single_image image=”8330″ img_size=”full”][\/vc_column][vc_column offset=”vc_col-lg-7 vc_col-md-12″ css=”.vc_custom_1516178424937{padding-right: 50px !important;padding-left: 50px !important;}”][vc_empty_space height=”25px”][vc_column_text]Harald Reinhart, M.D.,…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":6552,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"full-width.php","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/8327"}],"collection":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/comments?post=8327"}],"version-history":[{"count":1,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/8327\/revisions"}],"predecessor-version":[{"id":8331,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/8327\/revisions\/8331"}],"up":[{"embeddable":true,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/6552"}],"wp:attachment":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/media?parent=8327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}